8
Participants
Start Date
October 7, 2016
Primary Completion Date
March 21, 2017
Study Completion Date
March 21, 2017
Albiglutide
Albiglutide liquid drug product is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid drug product (50 mg). Subjects will receive albiglutide 50 mg through subcutaneous injection in the abdomen, thigh or upper arm region via auto-injector. Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).
Auto-injector
The auto-injector delivers the albiglutide liquid drug product in an injection volume of 1.0 mL for the 50 mg dose.
GSK Investigational Site, Columbia
GSK Investigational Site, Columbia
GSK Investigational Site, Conyers
GSK Investigational Site, Orlando
GSK Investigational Site, Hallandale
GSK Investigational Site, Miami
GSK Investigational Site, Miami
GSK Investigational Site, Clearwater
GSK Investigational Site, Bradenton
GSK Investigational Site, Columbus
GSK Investigational Site, Evansville
GSK Investigational Site, Kalamazoo
GSK Investigational Site, Chesterfield
GSK Investigational Site, Dallas
GSK Investigational Site, Arlington
GSK Investigational Site, Houston
GSK Investigational Site, Houston
GSK Investigational Site, Shavano Prk
GSK Investigational Site, Littleton
GSK Investigational Site, Phoenix
GSK Investigational Site, Lomita
GSK Investigational Site, West Hills
GSK Investigational Site, Spring Valley
GSK Investigational Site, Tustin
GSK Investigational Site, Fresno
GSK Investigational Site, Sacramento
GSK Investigational Site, Schertz
Lead Sponsor
GlaxoSmithKline
INDUSTRY